Targeted treatment of refractory primitive neuroectodermal tumor arising from an immature teratoma with crizotinib leading to a sustained response

Here we present a case of metastatic PNET which arose from an immature teratoma that was refractory to standard Ewing sarcoma chemotherapy. This PNET was determined to have elevated levels of ALK protein via IHC. The patient was treated with crizotinib on a palliative basis with a sustained response...

Descripción completa

Detalles Bibliográficos
Autores principales: Snyder, Benjamin M., Lion, Alex H., Helvie, Amy E., Marshall, Mark S., Ferguson, Michael J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9810838/
https://www.ncbi.nlm.nih.gov/pubmed/36619485
http://dx.doi.org/10.1002/ccr3.6779
_version_ 1784863393668136960
author Snyder, Benjamin M.
Lion, Alex H.
Helvie, Amy E.
Marshall, Mark S.
Ferguson, Michael J.
author_facet Snyder, Benjamin M.
Lion, Alex H.
Helvie, Amy E.
Marshall, Mark S.
Ferguson, Michael J.
author_sort Snyder, Benjamin M.
collection PubMed
description Here we present a case of metastatic PNET which arose from an immature teratoma that was refractory to standard Ewing sarcoma chemotherapy. This PNET was determined to have elevated levels of ALK protein via IHC. The patient was treated with crizotinib on a palliative basis with a sustained response.
format Online
Article
Text
id pubmed-9810838
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-98108382023-01-05 Targeted treatment of refractory primitive neuroectodermal tumor arising from an immature teratoma with crizotinib leading to a sustained response Snyder, Benjamin M. Lion, Alex H. Helvie, Amy E. Marshall, Mark S. Ferguson, Michael J. Clin Case Rep Case Report Here we present a case of metastatic PNET which arose from an immature teratoma that was refractory to standard Ewing sarcoma chemotherapy. This PNET was determined to have elevated levels of ALK protein via IHC. The patient was treated with crizotinib on a palliative basis with a sustained response. John Wiley and Sons Inc. 2023-01-03 /pmc/articles/PMC9810838/ /pubmed/36619485 http://dx.doi.org/10.1002/ccr3.6779 Text en © 2023 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Snyder, Benjamin M.
Lion, Alex H.
Helvie, Amy E.
Marshall, Mark S.
Ferguson, Michael J.
Targeted treatment of refractory primitive neuroectodermal tumor arising from an immature teratoma with crizotinib leading to a sustained response
title Targeted treatment of refractory primitive neuroectodermal tumor arising from an immature teratoma with crizotinib leading to a sustained response
title_full Targeted treatment of refractory primitive neuroectodermal tumor arising from an immature teratoma with crizotinib leading to a sustained response
title_fullStr Targeted treatment of refractory primitive neuroectodermal tumor arising from an immature teratoma with crizotinib leading to a sustained response
title_full_unstemmed Targeted treatment of refractory primitive neuroectodermal tumor arising from an immature teratoma with crizotinib leading to a sustained response
title_short Targeted treatment of refractory primitive neuroectodermal tumor arising from an immature teratoma with crizotinib leading to a sustained response
title_sort targeted treatment of refractory primitive neuroectodermal tumor arising from an immature teratoma with crizotinib leading to a sustained response
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9810838/
https://www.ncbi.nlm.nih.gov/pubmed/36619485
http://dx.doi.org/10.1002/ccr3.6779
work_keys_str_mv AT snyderbenjaminm targetedtreatmentofrefractoryprimitiveneuroectodermaltumorarisingfromanimmatureteratomawithcrizotinibleadingtoasustainedresponse
AT lionalexh targetedtreatmentofrefractoryprimitiveneuroectodermaltumorarisingfromanimmatureteratomawithcrizotinibleadingtoasustainedresponse
AT helvieamye targetedtreatmentofrefractoryprimitiveneuroectodermaltumorarisingfromanimmatureteratomawithcrizotinibleadingtoasustainedresponse
AT marshallmarks targetedtreatmentofrefractoryprimitiveneuroectodermaltumorarisingfromanimmatureteratomawithcrizotinibleadingtoasustainedresponse
AT fergusonmichaelj targetedtreatmentofrefractoryprimitiveneuroectodermaltumorarisingfromanimmatureteratomawithcrizotinibleadingtoasustainedresponse

Ejemplares similares